- Home
- ARR vs NVAX Comparison
ARR vs NVAX Comparison
Compare ARR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- NVAX
- Stock Information
- Founded
- ARR 2008
- NVAX 1987
- Country
- ARR United States
- NVAX United States
- Employees
- ARR N/A
- NVAX N/A
- Industry
- ARR Real Estate Investment Trusts
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARR Real Estate
- NVAX Health Care
- Exchange
- ARR Nasdaq
- NVAX Nasdaq
- Market Cap
- ARR 1.4B
- NVAX 1.3B
- IPO Year
- ARR N/A
- NVAX 1995
- Fundamental
- Price
- ARR $16.21
- NVAX $7.34
- Analyst Decision
- ARR Hold
- NVAX Buy
- Analyst Count
- ARR 5
- NVAX 5
- Target Price
- ARR $21.00
- NVAX $19.00
- AVG Volume (30 Days)
- ARR 2.3M
- NVAX 14.2M
- Earning Date
- ARR 07-23-2025
- NVAX 05-08-2025
- Dividend Yield
- ARR 17.77%
- NVAX N/A
- EPS Growth
- ARR N/A
- NVAX N/A
- EPS
- ARR N/A
- NVAX 2.97
- Revenue
- ARR $44,778,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- ARR $532.77
- NVAX $40.01
- Revenue Next Year
- ARR $15.62
- NVAX N/A
- P/E Ratio
- ARR N/A
- NVAX $2.47
- Revenue Growth
- ARR 41.14
- NVAX 25.92
- 52 Week Low
- ARR $13.18
- NVAX $5.01
- 52 Week High
- ARR $21.93
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- ARR 48.11
- NVAX 55.86
- Support Level
- ARR $15.61
- NVAX $6.84
- Resistance Level
- ARR $16.88
- NVAX $7.62
- Average True Range (ATR)
- ARR 0.30
- NVAX 0.55
- MACD
- ARR -0.05
- NVAX 0.07
- Stochastic Oscillator
- ARR 36.06
- NVAX 50.52
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.